Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H1N1 Vaccines GSK2340273A and GSK2340274A in Adults
NCT00985088Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Nov 2009
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of GSK2340273A and influenza vaccine (split virion, inactivated, H1N1) in influenza (8 arms), sponsored by GSK. Primary endpoints: Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain at Day 182, Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain at Day 182 and 2 more. Started Oct 2009; status: completed.
02
Drugs
GSK2340273Ainfluenza vaccine (split virion, inactivated, H1N1)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00985088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985088.